47
Representing Wellington Management Emerging Markets Equity Wellington Management Company, llp City of Fresno Retirement System 24 January 2012 Vera M. Trojan, CFA Senior Vice President, Partner Equity Portfolio Manager Charles C. Ruch, CFA Vice President Relationship Manager 22000354159/305205_0/305205/G2026

Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

Embed Size (px)

Citation preview

Page 1: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

Representing Wellington Management

Emerging Markets Equity

Wellington Management Company, llp

City of Fresno Retirement System

24 January 2012

Vera M. Trojan, CFASenior Vice President, PartnerEquity Portfolio Manager

Charles C. Ruch, CFAVice PresidentRelationship Manager

22000354159/305205_0/305205/G2026

Page 2: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

Appendix

Agenda

Section One

2000354167/305205_0/305205/305205

Wellington Management Firm Update and Relationship Review

Section Two Emerging Markets Equity Portfolio Review

Section Three Appendix and Disclosures

Page 3: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

W E L L I N G T O N M A N A G E M E N T

1

Page 4: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

Wellington ManagementUnique Organization

Appendix

2000003949/305205_0/G1039/G1039

Multiple investment approaches and research disciplines

Empowered portfolio teams

Independent, proprietary research

Career analysts

Freedom to disagree

Global

Investment Platform

Private partnership since 1979

Stable

Long-term orientation

Attract, retain, and motivate talent

Align interests with clients

Ownership Structure

Client-oriented

Performance-driven

Professional and collegial

Humanistic

A true “partnership”

Highest standards – ethics and integrity

Sustainable competitive advantage

Investment management only

Research for client portfolios only

People-intensive, not capital-intensive

Diversified

Global

Business ModelCulture

1

Page 5: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

Appendix

Wellington Management Today

Preliminary as of 31 December 2011

Assets•US$651

2000003956/305205_0/G1039/G1039

billionofclientassetsundermanagement•40%equity,46%fixedincome,14%multi-strategy

Resources•Over1,900employees•11offices

Clients•Over2,000institutionalclientsbasedinmorethan50countries

2

Page 6: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

Appendix

Investment ProfessionalsDepth, Experience, and Continuity

31 December 2011

2000003966/305205_0/G1039/G1039

Central ResearchGlobal Industry Analysis 51 19 10

Average Years of ExperienceAverage Years with Wellington Management

1810

Quantitative Analysis 11 17 8Global Macroanalysis 7 19 15

Technical Analysis 3 24 8Portfolio Coordinators 17 15 8

Management 10 19 12

EquitiesPortfolio Management 53 23 15

Average Years of ExperienceAverage Years with Wellington Management

1810

Research Analysis 62 13 6Product Management 23 19 8

Management 6 21 14

Fixed IncomePortfolio Management 51 18 10

Average Years of ExperienceAverage Years with Wellington Management

178

Credit Analysis 32 17 6Quantitative Analysis 13 17 7Product Management 26 16 6

Portfolio Analysis 24 12 6Management 5 23 9

Multi-StrategyAsset Allocation Portfolio Management 9 19 9

Average Years of ExperienceAverage Years with Wellington Management

188

Asset Allocation Analysis 12 15 7Product Management 7 20 9

TradingEquity and Fixed Income Traders 51 20 11 Average Years of Experience

Average Years with Wellington Management2011Management 7 24 12

Research Associates 47 7 5

Total Number of Investment Professionals 527

Number of Professionals

Average Years with Wellington Management

Average Years of Experience

3

Page 7: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

Appendix

City of Fresno Retirement SystemRelationship Review

18 September 2008 The City of Fresno Retirement System retained Wellington Management Company,

2000354185/305205_0/305205/283522

llp to manage approximately $34.7 million in a separately managed Emerging Markets Equity Portfolio for the City Employees and Fire and Police Employees Pension Plan

27 April 2009 Contribution: $5.0 million

27 November 2009 Withdrawal: $10.0 million

14 March 2011 Withdrawal: $5.0 million

31 December 2011 Market Value: $36.9 million

4

Page 8: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

W E L L I N G T O N M A N A G E M E N T

2

Page 9: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

Appendix

Emerging Markets EquityDistinguishing Characteristics

Rolling gross monthly returns for the Emerging Markets Composite versus the MSCI Emerging Markets Index.

2000211112/305205_0/G1123/G1123

| Gross performance results are net of commissions and other direct expenses, but before (gross of) advisory fees, custody charges, withholding taxes, and other indirect expenses, and include reinvestment of dividends. If all expenses were reflected, the performance shown would be lower. Actual fees will vary depending on, among other things, the applicable fee schedule and account size. For example, if US$100,000 was invested and experienced a 10% annual return compounded monthly for ten years, its ending value, without giving effect to the deduction of advisory fees, would be US$270,704 with an annualized compounded return of 10.47%. If an advisory fee of 0.95% of average net assets per year were deducted monthly for the ten-year period, the annualized compounded return would be 9.43% and the ending dollar value would be US$246,355. Information regarding the firm’s advisory fees is available upon request. Composite returns have the potential to be adjusted until reviewed and finalized 30 days following each calendar quarter end period. Past performance is no guarantee of future results. For use in one-on-one presentations only. This supplemental information complements the GIPS® compliant presentation provided in the attachment.

-20

-10

0

10

20

30

40

50

-20 -10 0 10 20 30 40 50

Emer

ging

Mar

kets

Equ

ity (%

)

MSCI Emerging Markets (%)

Consistent

Integrated Approach

“Boutique” with Deep Resources

Experienced

Above MSCI Emerging Markets

Below MSCI Emerging Markets

Rolling Gross Monthly 3-Year Trailing Returns30 September 2004 to 30 September 2011

5

Page 10: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

Emerging Markets EquityInvestment Objective and Approach

Appendix

Investment objectiveConsistently outperform the MSCI Emerging Markets Equity Index

Investment approachFundamental, proprietary research

Integrated Analytical Approach – country, sector, and stock

Focus on companies with compelling growth opportunities, attractive returns on capital

Opportunistic by style and market cap

2000312430/305205_0/G2026/G2026

6

Page 11: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

Appendix

Emerging Markets EquityPortfolio Management Team

2000239240/305205_0/G1123/G1123

Vera M. Trojan, CFA Equity Portfolio ManagerSenior Vice President MBA, Harvard Business School, 1987 28 years of professional experience

Bo Z. Meunier, CFA Equity Research AnalystDirector MBA, Babson College (Olin), 1998 16 years of professional experience

Jamie F. Rice, CFA Equity Research AnalystVice President AB, Harvard College, 1992 20 years of professional experience

Murali Srikantaiah Equity Research AnalystVice President MBA, Dartmouth College (Tuck), 2000 16 years of professional experience

7

Page 12: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

Appendix

Emerging Markets EquityPortfolio Management Team (continued)

2000282576/305205_0/G1123/G1123

David J. Palmisano, CFA Equity Research AnalystVice President MBA, Boston College, 2000 17 years of professional experience

Carolina S. Pierry Equity Research AnalystVice President MBA, Columbia University, 2007 14 years of professional experience

Muchemi J. Wandimi Research Associate

BS, University of Pennsylvania (Wharton), 2007 5 years of professional experience

Ted A. Gilchrist Investment DirectorDirector BA, University of Notre Dame, 1996 15 years of professional experience

8

Page 13: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

Appendix

Emerging Markets Equity“Boutique” with Deep Resources

*Association of Southeast Asian Nations (Philippines, Malaysia, Singapore, Thailand, Vietnam, Indonesia, Brunei Darussalam, Cambodia, Laos, Myanmar)

2000266697/305205_0/G1123/G1123

| 31 December 2011

Vera Trojan Portfolio Manager

Emerging Markets Debt Team

(15 members)

Currency Specialists

(2 members)

Diversified Portfolio Managers

(53 members)

Global Industry Analysts

(51 members)

Macroanalysts(7 members)

Bo MeunierChina, Real Estate

Carolina PierryEMEA

Muchemi WandimiSpecial Projects

Jamie RiceLatin America

Murali Srikantaiah

India, ASEAN*, Telecom

David PalmisanoSouth Korea,

Taiwan, Asian Technology

9

Page 14: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

Appendix

Emerging Markets EquityInvestment Process

The above characteristics are sought during the portfolio management process. Actual experience may not reflect all of these characteristics, or may be outside of stated ranges.

2000002012/305205_0/G1123/G1123

Emerging Markets Portfolio

Research Universe

Stocks•Most>US$4bil•Selected<US$4bil

Countries (30)

Sectors (10)

Company Analysis

Country/ Sector Analysis

•Systematicreview•Positivestructuraltrends

•Cyclicalinflectionpoints

•Growthdrivers•Winningstrategy•Strongfinancialposition

•Attractivevaluations

Portfolio Construction

•Upside,risk,andliquidity

•Buy/Selldiscipline

70 – 120Stocks

400 Stocks

15,000 Stocks

10

Page 15: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

Appendix

City of Fresno Retirement System EMEInvestment Returns (US$) Through 31 December 2011

*Performance inception date of the City of Fresno Retirement System portfolio is 30 September 2008.

2000354192/305205_0/305205/G2026

| The portfolio returns are reported gross of investment management fees and net of operating expenses since inception. | Returns for periods less than one year are not annualized.

Annualized Returns Since 4Q11 1 Yr 3 Yrs Inception* City of Fresno EME 4.1% -21.4% 18.0% 6.5%MSCI Emerging Markets 4.4 -18.2 20.4 7.5

2011 2010 2009 City of Fresno EME -21.4% 17.2% 78.2%MSCI Emerging Markets -18.2 19.2 79.0

11

Page 16: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

Appendix

MSCI Emerging Markets Index Returns – CountryFourth Quarter 2011

MSCI Index Performance (in USD)

Sources: FactSet, MSCI

2000349080/305205_0/303905/G2026

| As of 31 December 2011

Peru MalaysiaThailand

MexicoBrazil

ChileChina

Philippines

South Africa

RussiaSouth Korea

Indonesia

MSCI EM Index

ColombiaTaiwan

Czech Republic

HungaryPoland

MoroccoEgypt

IndiaTurkey

-20

-15

-10

-5

0

5

10

15

Retu

rn (%

)

12

Page 17: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

Appendix

MSCI Emerging Markets Index Returns – SectorFourth Quarter 2011

Sources: FactSet, MSCI

2000349081/305205_0/303905/G2026

| As of 31 December 2011

MSCI Index Performance (in USD)

Cons Staples

UtilitiesInfo Technology

EnergyMSCI EM Index

FinancialsCons Discretionary

Telecom Svcs

IndustrialsMaterials

Health Care

-4

-2

0

2

4

6

8

10

Retu

rn (%

)

13

Page 18: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

Appendix

City of Fresno Retirement System EMEPerformance by Country: Fourth Quarter 2011Portfolio: 4.1%; Benchmark: 4.4%

*Represents top and bottom five relative contributing countries

2000352168/305205_0/303797/G2026

| **Represents underweight position relative to the benchmark | As of 31 December 2011

200

100

0

-100

-200

Country Attribution – Value Added*

Basi

s po

ints

Country Allocation Security Selection

30

Taiwan

31

Turkey

4

SouthKorea

11

HongKong

24

Thailand

-11

Mexico

-1

Colombia

-14

SouthAfrica

-5

Brazil

-3

China

570 24 0

-143

-102

-12

-111

Selected Outperforming Countries Stocks Contributing to Performance Taiwan Hon Hai Precision, HTC**Turkey Turkiye Garanti Bank**, Turkiye Is Bankasi**

Selected Underperforming Countries Stocks Detracting from Performance China China Mobile, Shangri-La AsiaBrazil Companhia De Bebidas**, Braskem

14

Page 19: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

Appendix

City of Fresno Retirement System EMEPerformance by Sector: Fourth Quarter 2011Portfolio: 4.1%; Benchmark: 4.4%

*Represents underweight position relative to the benchmark

2000352169/305205_0/303797/G2026

| As of 31 December 2011

200

100

0

-100

-200

Sector Attribution – Value Added

Basi

s po

ints

Sector Allocation Security Selection

23

InfoTechnology

26

Materials

4

Industrials

-1

ConsDiscretionary

0

Utilities

0

Financials

-8

TelecomSvcs

-7

ConsStaples

-9

HealthCare

5

Energy

102

28

-31

-3 -26 -19 -25 -24 -51

Selected Outperforming Sectors Stocks Contributing to Performance Info Technology Samsung Electronics, Hon Hai PrecisionMaterials Vale*, MMC Norilsk Nickel*

Selected Underperforming Sectors Stocks Detracting from Performance Energy PacificRubialesEnergy,GSHoldingsHealthCare RanbaxyLaboratories,SinopharmGroup

15

Page 20: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

Appendix

MSCI Emerging Markets Index Returns – CountryTrailing Twelve Months

Sources: FactSet, MSCI

2000352179/305205_0/303797/G1871

| As of 31 December 2011

IndonesiaMalaysia

Philippines

ThailandCzech Republic

ColombiaSouth Korea

MexicoSouth Africa

MoroccoMSCI EM Index

ChinaRussia

ChileTaiwan

Peru BrazilPoland

HungaryTurkey

IndiaEgypt

-50

-40

-30

-20

-10

0

10

Retu

rn (%

)

MSCI Index Performance (in USD)

16

Page 21: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

Appendix

MSCI Emerging Markets Index Returns – SectorTrailing Twelve Months

Sources: FactSet, MSCI

2000352180/305205_0/303797/G1871

| As of 31 December 2011

Cons Staples

Telecom Svcs

Cons Discretionary

UtilitiesInfo Technology

EnergyMSCI EM Index

Health CareFinancials

MaterialsIndustrials

-30

-25

-20

-15

-10

-5

0

5

Retu

rn (%

)

MSCI Index Performance (in USD)

17

Page 22: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

Appendix

City of Fresno Retirement System EMEPerformance by Country: Trailing Twelve MonthsPortfolio: -21.4%; Benchmark: -18.2%

*Represents top and bottom five relative contributing countries

2000352177/305205_0/303797/G2026

| **Represents underweight position relative to the benchmark | As of 31 December 2011

100

50

0

-50

-100

-150

Country Attribution – Value Added*

Basi

s po

ints

Country Allocation Security Selection

23

Turkey

7

SouthKorea

-5

China

27

Thailand

2

Peru

-8

Russia

-25

SouthAfrica

-36

Indonesia

-48

Egypt

-13

Brazil

0 14 17

-20

3

-37 -23 -28 -27-69

Selected Outperforming Countries Stocks Contributing to Performance Turkey Turkiye Is Bankasi**, Akbank**South Korea Samsung Electronics, NCsoft

Selected Underperforming Countries Stocks Detracting from Performance Brazil Petrobras, OGX Petroleo e GasEgypt EFG-Hermes, Commercial International Bank

18

Page 23: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

Appendix

City of Fresno Retirement System EMEPerformance by Sector: Trailing Twelve MonthsPortfolio: -21.4%; Benchmark: -18.2%

*Represents underweight position relative to the benchmark.

2000352178/305205_0/303797/G2026

| As of 31 December 2011

400

200

0

-200

-400

Sector Attribution – Value Added

Basi

s po

ints

Sector Allocation Security Selection

24

InfoTechnology

-6

TelecomSvcs

-2

Utilities

12

Industrials

-20

HealthCare

35

Materials

4

Energy

12

ConsDiscretionary

-24

ConsStaples

21

Financials

1222

-20 -38 -14-78 -79 -95 -64

-173

Selected Outperforming Sectors Stocks Contributing to Performance Info Technology Samsung Electronics, NCsoftTelecom Svcs Philippine Long Distance, Axiata Group

Selected Underperforming Sectors Stocks Detracting from Performance Financials EFG-Hermes, Canara BankCons Staples X5 Retail Group, Companhia De Bebidas*

19

Page 24: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

Appendix

Emerging Markets Equity2012 Outlook

Challenging global cyclical outlook•Europe

2000347397/305205_0/303391/289817

inrecession•Chinarecoversinsecondhalfof2012•USdelaysfiscalconsolidation;continuestogrow

Globalmonetaryeasing•EuropeanCentralBanksupportingEuroareabanks•Inflationrecedinginemergingmarkets

Highmacroandfinancialvolatilitywillprevail•Politicsfocusinward,oneconomicchallenges

20

Page 25: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

Appendix

Emerging Markets EquityOpportunities

Valuations very compelling

Monetary policies ease as inflation abates

Global market share gains continue for leading companies

Weakness in home countries keeps foreigners away

Capital market reform: broader markets, and better capital allocators

Productivity gains continue with investment, education, and resource development

2000347396/305205_0/303391/289817

21

Page 26: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

Appendix

City of Fresno Retirement System EMELargest Active Positions – Stocks

As of 31 December 2011

2000352187/305205_0/303797/G2026

Portfolio MSCI Emerging Company Country Sector Weight MarketsIndex Difference Samsung Electronics South Korea Information Technology 6.7% 3.5% 3.2%Hon Hai Precision Taiwan Information Technology 3.8 0.8 3.0Vale Brazil Materials 0.0 2.1 -2.1China Mobile China Telecommunication Services 0.0 1.8 -1.8Gazprom Russia Energy 0.0 1.8 -1.8Sberbank Russia Financials 2.4 0.7 1.7Dongfeng Motor China Consumer Discretionary 1.6 0.1 1.5America Movil Mexico Telecommunication Services 0.0 1.4 -1.4Taiwan Semiconductor Taiwan Information Technology 3.1 1.9 1.2Hyundai Motor South Korea Consumer Discretionary 2.2 1.0 1.2

Number of Equity Names 99

22

Page 27: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

Appendix

City of Fresno Retirement System EMECountry Weights as of 31 December 2011

2000352190/305205_0/303797/296671

Emerging Markets Equity Portfolio MSCI EM Index20

18

16

14

12

10

8

6

4

2

0

% o

f Equ

ity

ThailandSouth Korea

RussiaBrazil

Other AsiaTaiwan

China MalaysiaOther EMEA

Other Latin America

MexicoIndia South Africa

23

Page 28: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

Appendix

City of Fresno Retirement System EMESector Weights as of 31 December 2011

2000352191/305205_0/303797/G1123

Emerging Markets Equity Portfolio MSCI EM Index30

25

20

15

10

5

0

% o

f Equ

ity

Info Technology

EnergyCons Discretionary

Health CareFinancials

UtilitiesIndustrials

Cons Staples

Telecom Svcs

Materials

24

Page 29: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

Appendix

City of Fresno Retirement System EMEPortfolio Characteristics as of 31 December 2011

*Weighted average P/E, P/B, and EPS growth based on 2011 estimates. For P/E and EPS, stocks without earnings are omitted from the calculations.

2000354207/305205_0/305205/G2026

| Sources: Datastream, Wellington Management. | **Tracking risk evaluated based on monthly returns. Tracking risk as of 31 December 2011.

Emerging MSCI Emerging Markets Equity Markets Index Size Asset-weighted Market Cap $43.2 bil $43.6 bilMedian Market Cap 12.1 4.6Over $10 billion 70% 65%$2 – 10 billion 27 31Under $2 billion 3 4

Valuation EPS Growth (Next Year)* 27.6% 23.0%P/E (Current)* 10.0x 10.4xP/B* 2.2x 1.9x

Risk Historical Tracking Risk (3-Year)** 3.6% Number of Countries 18 21Number of Companies 99 806

25

Page 30: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

W E L L I N G T O N M A N A G E M E N T

3

Page 31: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

Appendix

Emerging vs Developed MarketsRelative Performance

2000273175/305205_0/G1871/G1871

12/89 12/91 12/93 12/95 12/97 12/99 12/01 12/03 12/05 12/07 12/09 12/110

50

100

150

200

250

300

350

400

Inde

xed

Source: MSCI

296

MSCI Emerging Markets/MSCI World Index

A1

Appendix

Page 32: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

Appendix

Corrections in MSCI Emerging Markets Index in US$

2000273176/305205_0/G1871/G1871

500

12/89 12/91 12/93 12/95 12/97 12/99 12/01 12/03 12/05 12/07 12/09 12/11100

1,000

1,500

Source: MSCI | Y axis shown with logarithmic scale.

MSCI EM Index (US$)

1 Aug 90 to 16 Jan 91(121 days)32% Decline

22 Apr 92 to 24 Aug 92(89 days)19% Decline

16 Feb 94 to 9 May 94(55 days)19% Decline

22 Sep 94 to 9 Mar 95(121 days)33% Decline

10 Jul 97 to 5 Oct 98(323 days)58% DeclineAsian Financial Crisis

18 Apr 02 to 10 Oct 02(168 days)30% Decline

23 Jul 07 to 16 Aug 07(24 days)18% DeclineInitial US Sub-Prime Mtg Fears

10 May 06 to 13 Jun 06(25 days)24% Decline

3 Oct 05 to 19 Oct 05(16 days)9% Decline

12 Apr 04 to 17 May 04(26 days)20% DeclineStart of Fed Tightening

10 Feb 00 to 3 Oct 01(430 days)54% DeclineGlobal Correction

29 Oct 07 to 2 Mar 0960% DeclineGlobal Credit Crisis

A2

Appendix

Page 33: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

Appendix

World Growth to Weaken Further in 2012

Source: WMC Macro Team Global Economic Forecast Summary (December 2011)

2000250443/305205_0/G1871/G1871

Japan

United States

United Kingdom

Euro Area

Thailand

Brazil

South Korea

South Africa

Mexico

Indonesia

Russia

India

Poland

Taiwan

China

Chile

Turkey

-2 0 2 4 6 8 10

Percent

2011 2012 Forecast

GDP Growth Rate (%)

A3

Appendix

Page 34: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

Appendix

2012 Will Be a Year of Modest DecelerationIn Most Emerging Markets

2000250314/305205_0/G1871/G1871

Japan

Thailand

Brazil

United States

South Korea

South Africa

Mexico

Indonesia

Russia

India

United Kingdom

Poland

Taiwan

China

Euro Area

Chile

Turkey

-5 -4 -3 -2 -1 0 1 2 3

Percent

Source: WMC Macro Team Global Economic Forecast Summary (December 2012)

2012 Expected GDP Growth vs 2011

A4

Appendix

Page 35: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

Appendix

Inflationary Pressures Easing in Large Emerging Markets

2000250473/305205_0/G1871/G1871

11/09 1/10 3/10 5/10 7/10 9/10 11/10 1/11 3/11 5/11 7/11 9/11 11/110

2

4

6

8

10

12

Percen

t

Brazil Russia India* China

*All inflation rate numbers based on CPI, except for India which is based on PPI | Sources: Bloomberg, CEIN (China), PIB (India), FISS (Russia), IBGE (Brazil)

Y/Y Inflation Rate (%)

A5

Appendix

Page 36: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

Appendix

Monetary Easing in Emerging Markets

2000250477/305205_0/G1871/G1871

Hungary

Colombia

Mexico

Venezuela

Thailand

Czech Republic

India

Indonesia

Korea

Philippines

Poland

Russia

South Africa

Turkey

Taiwan

China

Chile

Malaysia

Argentina

Brazil

-1.5 -1.0 -0.5 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0

Percent

Source: Haver, Wellington Management (as of December 2011)

Overnight / Policy Interest Rates, Percentage Point Change, Last Three Months, Latest Data Available

A6

Appendix

Page 37: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

Appendix

Emerging Markets Dependent on Exports

2000220133/305205_0/G1871/G1871

82 84 86 88 90 92 94 96 98 00 02 04 06 08 1010

15

20

25

30

35

Percen

t

00 01 02 03 04 05 06 07 08 09 1020

24

28

32

36

40

Percen

t

Sources: IMF, Haver

Emerging Markets, Exports as % of GDP

Share of Emerging Market Exports Going to Emerging Markets

Emerging Market exports have roughly doubled as a proportion of GDP over the past two decades

In the last decade, exports between emerging economies have increased 50% as a proportion if emerging market exports

A7

Appendix

Page 38: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

Appendix

Emerging Markets Are Becoming Increasingly Important

2000220150/305205_0/G1871/G1871

1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 201015

17

19

21

23

25

27

29

31

33

35

Percent

Source: IMF

Emerging & Developing Economies GDP (in Current USD) Share of World Total (%)

A8

Appendix

Page 39: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

Appendix

The Structural CaseEmerging Markets: Favorable Demographics

2000018432/305205_0/G1871/G1871

Japan

Russia

Germany

Italy

France

UK

Korea

China

US

Canada

Australia

Brazil

Mexico

India

-6 -4 -2 0 2 4 6 8 10 12

Sources: UN Forecasts generated in 2008

5-Year % Ch in Working Age Population, Ages 15 – 64, 2008 – 2012

A9

Appendix

Page 40: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

Appendix

International Liquidity Declining

2000063757/305205_0/G1871/G1871

Argentina

Turkey

Poland

Venezuela

Indonesia

Thailand

Czech Republic

Russia

South Africa

India

Malaysia

China

Korea

Hungary

Colombia

Brazil

Mexico

Chile

Philippines

-40 -30 -20 -10 0 10 20 30 40 50

Latest 3-Month Annualized

Sources: Haver and CEIC

International Reserves: 3-Month Annualized Growth Rate, Latest Available

A10

Appendix

Page 41: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

Appendix

External Vulnerability: Uses vs Sources of Foreign Exchange

2000220157/305205_0/G1871/G1871

AlgeriaChina

Iran Peru RussiaBrazil

ThailandIndonesia

Venezuela

Philippines

Malaysia

Colombia

LebanonKorea

IndiaChile

Argentina

South Africa

MexicoPoland

EcuadorHungary

Czech Republic

EgyptTunisia

RomaniaMorocco

Turkey

0.0

0.2

0.4

0.6

0.8

1.0

1.2

Perc

ent

Financial Vulnerability is defined as Debt Service + Imports/(Gross International Reserves – IMF Credit) + Exports + Net Transfers | Source: Institute of International Finance

2012 Forecast of Use vs Sources of Foreign Exchange

A11

Appendix

Page 42: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

Appendix

Where Are the World’s Fiscal Basket Cases?

2000018444/305205_0/G1871/G1871

2001 2003 2005 2007 2009 2011 2013 201530

40

50

60

70

80

90

100

110

Perc

ent o

f GDP

Advanced Economies

Emerging and Developing Economies

Source: IMF

Government Debt to GDP, 2000 – 2015

A12

Appendix

Page 43: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

Appendix

Emerging vs Developed MarketsCompany Valuations: Relative Price-to-Earnings

2000273177/305205_0/G1871/G1871

12/96 12/97 12/98 12/99 12/00 12/01 12/02 12/03 12/04 12/05 12/06 12/07 12/08 12/09 12/10 12/110

5

10

15

20

25

30

35

40

P/E

(Tra

iling

12

Mon

ths)

MSCI Emerging Markets P/E MSCI World ex Japan P/E

Source: MSCI

10.7x

12.8x

A13

Appendix

Page 44: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

Appendix

Emerging vs Developed MarketsCompany Valuations: Relative Price-to-Book

2000273179/305205_0/G1871/G1871

12/96 12/97 12/98 12/99 12/00 12/01 12/02 12/03 12/04 12/05 12/06 12/07 12/08 12/09 12/10 12/110.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

5.0

P/B

MSCI Emerging Markets P/BV MSCI World ex Japan P/BV

Source: MSCI

1.6x 1.7x

A14

Appendix

Page 45: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

Appendix

Emerging vs Developed MarketsCompany Valuations: Relative Return on Equity

2000273178/305205_0/G1871/G1871

12/95 12/96 12/97 12/98 12/99 12/00 12/01 12/02 12/03 12/04 12/05 12/06 12/07 12/08 12/09 12/10 12/110

3

6

9

12

15

18

ROE

MSCI EM ROE MSCI World ROE

ROE is defined as Earnings per Share/Book Value per share expressed as a percentage. | Source: MSCI

14.7

12.3

A15

Appendix

Page 46: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

Appendix

Important Notice

Wellington Management Company, llp is an independently owned, SEC-registered Investment Adviser that, along with its subsidiaries and affiliates (collectively, Wellington Management), provides investment management and investment advisory services to institutions around the world. Located in Boston, Massachusetts, Wellington Management also has offices in: Chicago, Illinois; Radnor, Pennsylvania; San Francisco, California; Beijing; Frankfurt; Hong Kong; London; Singapore; Sydney; and Tokyo. This material is prepared for, and authorized for internal use by, designated institutional and professional investors and their consultants or for such other use as may be authorized by Wellington Management Company, llp or its affiliates. This material and/or its contents are current at the time of writing and may not be reproduced or distributed in whole or in part, for any purpose, without the express written consent of Wellington Management. This material is not intended to constitute investment advice or an offer to sell, or the solicitation of an offer to purchase shares or other securities. Investors should always obtain and read an up

2000000298/305205_0/G1422/G1422

-to-date investment services description or prospectus before deciding whether to appoint an investment manager or to invest in a fund. Any views expressed herein are those of the author(s), are based on available information, and are subject to change without notice. Individual portfolio management teams may hold different views and may make different investment decisions for different clients.

In the UK, this material is provided by Wellington Management International Limited, a firm authorized and regulated by the Financial Services Authority (FSA). This material is directed only at persons (Relevant Persons) who are classified as eligible counterparties or professional clients under the rules of the FSA. This material must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment service to which this material relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. Persons residing in Austria and France are directed to contact only the Managing Director at Wellington Management International Limited in the United Kingdom for further information. In Germany, this material is provided by Wellington Management International Limited, Niederlassung Deutschland, the German branch of Wellington Management International Limited, which is authorized and regulated by the FSA and in respect of certain of its activities by the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht – BaFin). This material is directed only at persons (Relevant Persons) who are classified as eligible counterparties or professional clients under the German Securities Trading Act. This material must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment service to which this material relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. This material does not constitute financial analysis within the meaning of Section 34b of the German Securities Trading Act, does not meet all legal requirements designed to guarantee the independence of financial analyses, and is not subject to any prohibition on dealing ahead of the publication of financial analyses. This material does not constitute a prospectus for the purposes of the German Investment Fund Act, the German Securities Sales Prospectus Act or the German Securities Prospectus Act. In Hong Kong, this material is provided by Wellington Global Investment Management Limited, a corporation licensed by the Securities and Futures Commission to conduct Type 1 (dealing in securities), Type 4 (advising on securities), and Type 9 (asset management) regulated activities, on the basis that you are a Professional Investor as defined in the Securities and Futures Ordinance. By accepting this material you acknowledge and agree that this material is provided for your use only and that you will not distribute or otherwise make this material available to a person who is not a Professional Investor as defined in the Ordinance. In Singapore, Wellington Management conducts its financial services business through Wellington International Management Company Pte Ltd (Registration Number 199504987R). In Australia, Wellington International Management Company Pte Ltd (WIM) has authorized the issue of this material for use solely by wholesale clients (as defined in the Corporations Act 2001) of WIM or of any of its related bodies corporate, or by wholesale clients who are considering investing in funds of which WIM or any of its related bodies corporate is an investment manager. By accepting this material, a wholesale client agrees not to reproduce or distribute any part of the material, nor make it available to any retail client, without WIM’s prior written consent. Wellington Management Company, llp is exempt from the requirement to hold an Australian financial services licence (AFSL) under the Corporations Act 2001 in respect of financial services, in reliance on class order 03/1100, a copy of which may be obtained at the web site of the Australian Securities and Investments Commission, http://www.asic.gov.au. The class order exempts a registered investment adviser regulated by the SEC, among others, from the need to hold an AFSL for financial services provided to Australian wholesale clients on certain conditions. Financial services provided by Wellington Management Company, llp are regulated by the SEC under the laws and regulatory requirements of the United States, which are different from the laws applying in Australia. In Japan, Wellington International Management Company Pte Ltd has been registered as a Financial Instruments Firm with registered number: Director General of Kanto Local Finance Bureau (Kin-Sho) Number 428. WIM is a member of the Japan Securities Investment Advisers Association (JSIAA) and the Investment Trusts Association, Japan (ITA).

©2012 Wellington Management. All rights reserved. | As of January 2012

Page 47: Emerging Markets Equity - Fresno · Emerging Markets Equity ... Ownership Structure Client-oriented Performance-driven ... Health Care Ranbaxy Laboratories, Sinopharm Group 15

2000000384/305205_0/G2332/G2308

Wellington Management Composite: Emerging Markets Equity Schedule of Performance Returns from 01 January 2001 to 31 December 2010

EMGMKTTOT Generated on: 10 October 2011

PeriodGross

Return (%) Net

Return (%) Benchmark Return (%)

Number of Accounts

Internal Dispersion (%)

Composite Mkt. Value (USD Mil)

Total Firm Assets (USD Mil)

2001 4.22 3.18 -2.37 N/M N/M 367 311,372 2002 -4.15 -5.11 -6.00 N/M N/M 5 302,863 2003 62.68 61.12 56.28 N/M N/M 78 393,992 2004 27.14 25.90 25.95 N/M N/M 246 469,884 2005 36.06 34.73 34.54 10 0.5 1,356 520,693 2006 35.13 33.81 32.59 11 1.0 2,522 575,492 2007 47.22 45.80 39.78 11 0.8 3,653 588,376 2008 -50.52 -51.04 -53.18 15 0.3 2,183 419,641 2009 76.16 74.48 79.02 19 1.2 6,085 537,384 2010 16.96 15.81 19.20 29 0.5 10,428 633,922

Benchmark: MSCI Emerging Markets

N/M: For years where there are five or fewer accounts throughout the performance period, Internal Dispersion and Number of Accounts are not meaningful. Composite Description: Accounts included in the Emerging Markets Equity Composite seek to achieve returns above the MSCI Emerging Markets Index by investing in non-US equity securities of emerging market countries, including countries outside the MSCI Emerging Markets Index.

Composite Creation Date: The composite creation date is February 2003.

Composite Membership: All fully discretionary, fee paying accounts are eligible for inclusion in the composite.

Fee Schedule: The US institutional separate account fee schedule for this product is:

Market Value Annual FeeOn the first US$25 million 1.00% On the next US$25 million 0.90 Over US$50 million 0.80 Composite Name Change: As of November 2010, the composite name changed from Emerging Markets to Emerging Markets Equity. The name change has not resulted in any material changes to the style or investment management of this composite or approach.

Firm: For purposes of GIPS® compliance, the Firm is defined as all accounts managed by Wellington Management Company, LLP, an independently owned, SEC-registered investment adviser which, along with its subsidiaries and affiliates (collectively, Wellington Management), provides investment advisory services to institutions around the world. Located in Boston, Massachusetts, WellingtonManagement also has offices in Chicago, Illinois; Radnor, Pennsylvania; San Francisco, California; Beijing; Frankfurt; Hong Kong; London; Singapore; Sydney; and Tokyo.

GIPS®: Wellington Management claims compliance with the Global Investment Performance Standards (GIPS®) and has prepared and presented this report in compliance with the GIPS® standards. Wellington Management has been independently verified for the periods 1 January 1993 to 31 December 2010. The verification report is available upon request. Verification assesses whether (1) the

firm has complied with all the composite construction requirements of the GIPS® standards on a firm-wide basis and (2) the firm's policies and procedures are designed to calculate and present performance in compliance with the GIPS® standards. Verification does not ensure the accuracy of any specific composite presentation.

Performance Calculation: Gross performance results are net of trading expenses. Net performance returns are net of a model investment management fee and are calculated by subtracting 1/12th of the highest applicable fee on a monthly basis from the composite gross returns. Returns, market values, and assets are reported in USD except when otherwise noted. Returns, market values and assets reported in currencies other than USD are calculated by converting the USD monthly return and assets using theappropriate exchange rate (official 4:00 p.m. London closing spot rates). Policies for valuing portfolios, calculating performance, and preparing compliant presentations are available upon request.

Internal Dispersion: The dispersion measure presented is the asset-weighted standard deviation. The asset-weighted standard deviation measures the dispersion of individual account returns relative to the asset-weighted composite return. Only accounts that have been included in the composite for the full period are included in the standard deviation calculation. Limitations imposed by client guidelines or by law on an account's ability to invest in certain securities or instruments, such as IPO securities, and/or implementation of the firm's Trade Allocation Policies and Procedures, may cause the account's performance to differ from that of the composite.

Composite Listing: Wellington Management's list of composite descriptions is available upon request.

Other Matters: This material contains summary information regarding the investment approach described herein and is not a complete description of the investment objectives, policies, guidelines, or portfolio management and research that supports thisinvestment approach. Any decision to engage Wellington Management should be based upon a review of the terms of the investment management agreement and the specific investment objectives, policies, and guidelines that apply under the terms of such agreement.

Past Performance: Past performance is no guarantee of future results.